PMID- 10963888
OWN - NLM
STAT- MEDLINE
DCOM- 20001004
LR  - 20190701
IS  - 0304-3940 (Print)
IS  - 0304-3940 (Linking)
VI  - 290
IP  - 3
DP  - 2000 Sep 1
TI  - Intracerebroventricular administration of the beta(3)-adrenoceptor agonist CL 
      316243 causes Fos immunoreactivity in discrete regions of rat hypothalamus.
PG  - 161-4
AB  - Intracerebroventricular (i.c.v.) administration of the beta(3)-AR agonist 
      BRL37344 causes dose dependent decreases in food intake in rats suggesting a role 
      for beta(3)-AR in the central control of feeding. We have conducted experiments 
      investigating the effects of i.c.v. administration of the selective beta(3)-AR 
      agonist CL316243 on Fos expression to determine whether beta(3)-AR stimulation 
      affects neurones within specific brain nuclei. Significantly higher numbers of 
      Fos positive cells were found in the rats treated i.c.v. with CL316243 compared 
      with control rats in the paraventricular hypothalamus, lateral hypothalamic area, 
      ventromedial hypothalamic nucleus and dorsal hypothalamic area. Pre-treatment 
      with the selective beta(3)-AR antagonist SR59230A resulted in a significant 
      decrease in the number of Fos positive cells in all those areas compared with 
      rats treated with CL316243 alone. These experiments demonstrate that i.c.v. 
      administration of selective beta(3)-AR agonist causes neuronal activation in 
      hypothalamic areas important in the central regulation of appetite via a 
      beta(3)-AR mediated effect.
FAU - Castillo-Melendez, M
AU  - Castillo-Melendez M
AD  - Department of Pharmacology, Monash University, 3800, Victoria, Australia. 
      margie.zakhem@med.monash.edu.au
FAU - McKinley, M J
AU  - McKinley MJ
FAU - Summers, R J
AU  - Summers RJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Ireland
TA  - Neurosci Lett
JT  - Neuroscience letters
JID - 7600130
RN  - 0 (Adrenergic beta-Agonists)
RN  - 0 (Dioxoles)
RN  - 0 (Proto-Oncogene Proteins c-fos)
RN  - 0 (Receptors, Adrenergic, beta)
RN  - 0 (Receptors, Adrenergic, beta-3)
RN  - 138908-40-4 (disodium 
      (R,R)-5-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)-amino)propyl)-1,3-benzodioxole-2,3-dicarboxylate)
SB  - IM
MH  - Adrenergic beta-Agonists/*pharmacology
MH  - Animals
MH  - Dioxoles/*pharmacology
MH  - Eating/*drug effects/physiology
MH  - Hypothalamus/cytology/*drug effects/*metabolism
MH  - Injections, Intraventricular
MH  - Male
MH  - Neurons/cytology/drug effects/metabolism
MH  - Obesity/drug therapy/pathology/physiopathology
MH  - Proto-Oncogene Proteins c-fos/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Adrenergic, beta/*drug effects/*metabolism
MH  - Receptors, Adrenergic, beta-3
EDAT- 2000/08/30 11:00
MHDA- 2000/10/07 11:01
CRDT- 2000/08/30 11:00
PHST- 2000/08/30 11:00 [pubmed]
PHST- 2000/10/07 11:01 [medline]
PHST- 2000/08/30 11:00 [entrez]
AID - S0304394000013598 [pii]
AID - 10.1016/s0304-3940(00)01359-8 [doi]
PST - ppublish
SO  - Neurosci Lett. 2000 Sep 1;290(3):161-4. doi: 10.1016/s0304-3940(00)01359-8.